Related Experiment Video

Updated: Dec 22, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K

Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country

Mortada El-Shabrawi1, Sherif Baroudy1, Fetouh Hassanin2

  • 1Cairo University, Cairo, Egypt.

Acta Paediatrica (Oslo, Norway : 1992)
|May 3, 2020
PubMed

Insights

Direct-acting antiviral (DAA) therapies like Sofosbuvir/Ledipasvir and Sofosbuvir/Daclatasvir demonstrate superior efficacy and safety for treating chronic hepatitis C virus (HCV) infection in children compared to Interferon/Ribavirin.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Infectious Diseases

Background:

  • Chronic hepatitis C virus (HCV) infection poses long-term health risks.
  • Effective treatment options are crucial for pediatric patients to achieve sustained virologic response (SVR).
  • Evaluating treatment outcomes and safety profiles in children is essential for guiding clinical practice.

Purpose of the Study:

  • To compare the efficacy and safety of Interferon (IFN) plus Ribavirin (RBV) versus direct-acting antiviral (DAA) therapies in pediatric outpatients with chronic HCV.
  • To assess sustained virologic response (SVR) rates and adverse events in children treated with different HCV regimens.

Main Methods:

  • A cohort of 60 pediatric patients (6-18 years) with chronic HCV infection was studied.
  • Group 1 (21 patients) received IFN/RBV therapy.
  • Group 2 (39 patients) received dual DAA therapy (Sofosbuvir/Ledipasvir or Sofosbuvir/Daclatasvir).

Main Results:

  • IFN/RBV therapy achieved a 57.1% SVR rate, with all patients experiencing short-term side effects. Six patients required subsequent DAA treatment.
  • DAA therapies (Sofosbuvir/Ledipasvir and Sofosbuvir/Daclatasvir) resulted in 100% SVR.
  • DAA treatment showed negligible short-term side effects in most patients, with fibrosis regression observed in some cases.

Conclusions:

  • Dual DAA therapy (Sofosbuvir/Ledipasvir and Sofosbuvir/Daclatasvir) is highly effective and safe for treating chronic HCV in children.
  • IFN/RBV therapy is less effective and associated with more side effects in pediatric HCV patients.
  • Successful HCV treatment may halt or even reverse liver fibrosis in children.
Abstract

Keywords:
DAAsHCVSVRinterferonpaediatrics

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

376
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
224
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
156
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
170